Fig. 2

BLM-induced pulmonary fibrosis in wild-type (WT) and Scgb3a2-transgenic (TG) mice. a Body weight curves of mice intubated and treated with BLM on day 0, followed by necropsy on day 63. Body weights are shown as the percentage of Day 0 weight set as 100 %. *P < 0.05, WT-BLM group vs. TG-BLM, **P < 0.01, BLM-treated groups vs. PBS-treated groups. b Whole lung H&E images of WT and TG lungs at 3 weeks (BLM 3 W), 6 weeks (BLM 6 W), and 9 weeks (BLM 9 W) post-BLM treatment, and their corresponding PBS-treated lungs collected at 3 W (PBS) as control. Magnification 40X images were stitched. c Masson Trichrome staining of lung sections of WT and TG mice at 3, 6, and 9 weeks post-BLM treatment. Magnification, 100X. d Ashcroft scores of BLM-induced damaged areas at 3, 6, and 9 weeks post-BLM treatment. PBS control levels are those from 3 W. e Hydroxyproline content at 3, 6, and 9 weeks post-BLM treatment. PBS control levels are those from 3 W. N > 6 in each group. The results are shown as the mean ± SD. *P < 0.05, NS, not significant. Statistical analysis was carried out by using student’s t-test